{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:46:06Z","timestamp":1791607566815,"version":"4.3.4"},"reference-count":178,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.jaci.2015.05.052","type":"journal-article","created":{"date-parts":[[2015,9,3]],"date-time":"2015-09-03T08:18:34Z","timestamp":1441268314000},"page":"531-545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":140,"title":["Therapeutic approaches to asthma\u2013chronic obstructive pulmonary disease overlap syndromes"],"prefix":"10.1016","volume":"136","author":[{"given":"Peter J.","family":"Barnes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2015.05.052_bib1","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/thx.2008.108027","article-title":"The overlap syndrome of asthma and COPD: what are its features and how important is it?","volume":"64","author":"Gibson","year":"2009","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2015.05.052_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/MCP.0000000000000118","article-title":"The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges","volume":"21","author":"Barrecheguren","year":"2015","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1440-1843.2006.00784.x","article-title":"Inflammatory subtypes in asthma: assessment and identification using induced sputum","volume":"11","author":"Simpson","year":"2006","journal-title":"Respirology"},{"key":"10.1016\/j.jaci.2015.05.052_bib4","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1164\/ajrccm.162.5.9910112","article-title":"Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease","volume":"162","author":"Papi","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/thx.2004.032516","article-title":"Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease","volume":"60","author":"Brightling","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2015.05.052_bib6","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1183\/09031936.00146306","article-title":"Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial","volume":"29","author":"Siva","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2015.05.052_bib7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1164\/rccm.201108-1553OC","article-title":"Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial","volume":"186","author":"Bafadhel","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib8","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1164\/ajrccm.155.2.9032192","article-title":"Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD","volume":"155","author":"Keatings","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000330667","article-title":"Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease","volume":"83","author":"Bafadhel","year":"2012","journal-title":"Respiration"},{"key":"10.1016\/j.jaci.2015.05.052_bib10","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib11","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib13","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib14","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S2213-2600(14)70187-0","article-title":"Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"2","author":"Brightling","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib15","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000334900","article-title":"IL-6 and IL-13 in induced sputum of COPD and asthma patients: correlation with respiratory tests","volume":"84","author":"Grubek-Jaworska","year":"2012","journal-title":"Respiration"},{"key":"10.1016\/j.jaci.2015.05.052_bib17","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.jaci.2006.02.013","article-title":"Cytokine production by bronchoalveolar lavage T lymphocytes in chronic obstructive pulmonary disease","volume":"117","author":"Barczyk","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.05.052_bib18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.alit.2014.07.003","article-title":"Phenotype of asthma related with high serum periostin levels","volume":"64","author":"Matsusaka","year":"2015","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaci.2015.05.052_bib19","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1164\/rccm.201403-0562LE","article-title":"Osteopontin and periostin are associated with a 20-year decline of pulmonary function in patients with asthma","volume":"190","author":"Kanemitsu","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib20","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2174\/156652408785160952","article-title":"Role of GATA-3 in allergic diseases","volume":"8","author":"Barnes","year":"2008","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib21","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jaci.2007.12.1175","article-title":"Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme","volume":"121","author":"Sel","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.05.052_bib22","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1411776","article-title":"Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme","volume":"372","author":"Krug","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib23","doi-asserted-by":"crossref","first-page":"8183","DOI":"10.4049\/jimmunol.174.12.8183","article-title":"Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity","volume":"174","author":"Ying","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2015.05.052_bib24","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","article-title":"Effects of an anti-TSLP antibody on allergen-induced asthmatic responses","volume":"370","author":"Gauvreau","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib25","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.4049\/jimmunol.181.4.2790","article-title":"Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease","volume":"181","author":"Ying","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2015.05.052_bib26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.anai.2012.04.004","article-title":"CRTH2 antagonists in the treatment of allergic responses involving TH2 cells, basophils, and eosinophils","volume":"109","author":"Townley","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2015.05.052_bib27","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/all.12451","article-title":"Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459","volume":"69","author":"Pettipher","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2015.05.052_bib28","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.rmed.2013.06.006","article-title":"Efficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD","volume":"107","author":"Snell","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib29","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.coi.2012.08.009","article-title":"Type 2 innate lymphoid cells: new players in asthma and allergy","volume":"24","author":"Scanlon","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaci.2015.05.052_bib30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.it.2015.01.005","article-title":"Lung ILC2s link innate and adaptive responses in allergic inflammation","volume":"36","author":"Martinez-Gonzalez","year":"2015","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jaci.2015.05.052_bib31","doi-asserted-by":"crossref","first-page":"L619","DOI":"10.1152\/ajplung.00305.2014","article-title":"Increased IL-33 expression in chronic obstructive pulmonary disease","volume":"308","author":"Xia","year":"2015","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jaci.2015.05.052_bib32","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1172\/JCI65570","article-title":"Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease","volume":"123","author":"Byers","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2015.05.052_bib33","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.immuni.2015.02.011","article-title":"Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection","volume":"42","author":"Kearley","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2015.05.052_bib34","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jaci.2007.01.015","article-title":"New molecular targets for the treatment of neutrophilic diseases","volume":"119","author":"Barnes","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.05.052_bib35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1358\/dof.2011.36.6.1622072","article-title":"Chemokine receptor CXCR2 antagonism to prevent airway inflammation","volume":"36","author":"Donnelly","year":"2011","journal-title":"Drugs Future"},{"key":"10.1016\/j.jaci.2015.05.052_bib36","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/09031936.00048509","article-title":"SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects","volume":"35","author":"Holz","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2015.05.052_bib37","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2125.2011.03968.x","article-title":"SB-656933, a novel CXCR2 selective antagonist, inhibits ex\u00a0vivo neutrophil activation and ozone-induced airway inflammation in humans","volume":"72","author":"Lazaar","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2015.05.052_bib38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/1465-9921-14-137","article-title":"Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist","volume":"14","author":"Leaker","year":"2013","journal-title":"Respir Res"},{"issue":"suppl","key":"10.1016\/j.jaci.2015.05.052_bib39","first-page":"38S","article-title":"Safety and efficacy of SCH527123, a novel CXCR2 antagonist, in patients with COPD","volume":"36","author":"Magnussen","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2015.05.052_bib40","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1164\/rccm.201405-0992OC","article-title":"CXCR2 antagonist MK-7123-A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease","volume":"191","author":"Rennard","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib41","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1365-2222.2012.04014.x","article-title":"Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial","volume":"42","author":"Nair","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2015.05.052_bib42","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1164\/rccm.200607-995OC","article-title":"The safety and efficacy of infliximab in moderate-to-severe chronic obstructive pulmonary disease","volume":"175","author":"Rennard","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib43","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000117386","article-title":"Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study","volume":"76","author":"Dentener","year":"2008","journal-title":"Respiration"},{"key":"10.1016\/j.jaci.2015.05.052_bib44","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1164\/rccm.200809-1512OC","article-title":"A randomized, double-blind, placebo-controlled study of TNF-a blockade in severe persistent asthma","volume":"179","author":"Wenzel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pupt.2015.01.005","article-title":"Canakinumab for the treatment of chronic obstructive pulmonary disease","volume":"31","author":"Rogliani","year":"2015","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaci.2015.05.052_bib46","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1378\/chest.13-1885","article-title":"Inflammasomes in respiratory disease: from bench to bedside","volume":"145","author":"Brusselle","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2015.05.052_bib47","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/nri2725","article-title":"NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?","volume":"10","author":"Tschopp","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2015.05.052_bib48","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.pharmthera.2011.03.007","article-title":"The role of the NLRP3 inflammasome in the pathogenesis of airway disease","volume":"130","author":"Birrell","year":"2011","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jaci.2015.05.052_bib49","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1007\/s00018-012-0962-0","article-title":"Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age-related diseases","volume":"69","author":"Salminen","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jaci.2015.05.052_bib50","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1183\/09031936.00105013","article-title":"Elevated expression of the NLRP3 inflammasome in neutrophilic asthma","volume":"43","author":"Simpson","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2015.05.052_bib51","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/thoraxjnl-2012-203062","article-title":"Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD","volume":"69","author":"Di Stefano","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2015.05.052_bib52","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib53","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev-physiol-021909-135926","article-title":"TH17 cells in asthma and COPD","volume":"72","author":"Alcorn","year":"2010","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.jaci.2015.05.052_bib54","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1164\/rccm.201007-1196PP","article-title":"Innate and adaptive interleukin-17-producing lymphocytes in chronic inflammatory lung disorders","volume":"183","author":"Vanaudenaerde","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib55","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1378\/chest.09-3058","article-title":"Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD","volume":"138","author":"Doe","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2015.05.052_bib56","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1365-2249.2009.03965.x","article-title":"Th17-related cytokine expression is increased in the bronchial mucosa of stable COPD patients","volume":"157","author":"Di Stefano","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2015.05.052_bib57","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1465-9921-7-135","article-title":"IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx?","volume":"7","author":"Bullens","year":"2006","journal-title":"Respir Res"},{"key":"10.1016\/j.jaci.2015.05.052_bib58","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1042\/CS20100417","article-title":"Regulation of IL-17 in chronic inflammation in the human lung","volume":"120","author":"Pridgeon","year":"2011","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jaci.2015.05.052_bib59","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jaci.2009.02.024","article-title":"T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma","volume":"123","author":"Al-Ramli","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.05.052_bib60","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1164\/rccm.201405-0859PP","article-title":"IL-17 in severe asthma. Where do we stand?","volume":"190","author":"Chesne","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib61","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tips.2008.11.004","article-title":"Interleukin-17 as a drug target in human disease","volume":"30","author":"Ivanov","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jaci.2015.05.052_bib62","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1164\/rccm.201212-2318OC","article-title":"Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma","volume":"188","author":"Busse","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib63","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nbt.1903","article-title":"Therapeutic targeting of the IL-12\/23 pathways: generation and characterization of ustekinumab","volume":"29","author":"Benson","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jaci.2015.05.052_bib64","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaci.2007.10.011","article-title":"Sputum indoleamine-2, 3-dioxygenase activity is increased in asthmatic airways by using inhaled corticosteroids","volume":"121","author":"Maneechotesuwan","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.05.052_bib65","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/thoraxjnl-2012-202127","article-title":"Decreased indoleamine 2,3-dioxygenase activity and IL-10\/IL-17A ratio in patients with COPD","volume":"68","author":"Maneechotesuwan","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2015.05.052_bib66","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/cea.12067","article-title":"Statins enhance the effects of corticosteroids on the balance between regulatory T cells and Th17 cells","volume":"43","author":"Maneechotesuwan","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2015.05.052_bib67","doi-asserted-by":"crossref","DOI":"10.1378\/chest.14-3138","article-title":"Simvastatin suppressses airway IL-17 and upregulates IL-10 in patients with stable COPD","author":"Maneechotesuwan","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2015.05.052_bib68","doi-asserted-by":"crossref","first-page":"6988","DOI":"10.4049\/jimmunol.180.10.6988","article-title":"Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes","volume":"180","author":"Zhang","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2015.05.052_bib69","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/intimm\/dxp037","article-title":"Protein geranylgeranylation regulates the balance between Th17 cells and Foxp3+ regulatory T cells","volume":"21","author":"Kagami","year":"2009","journal-title":"Int Immunol"},{"key":"10.1016\/j.jaci.2015.05.052_bib70","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1378\/chest.10-1914","article-title":"p38 mitogen-activated protein kinase pathways in asthma and COPD","volume":"139","author":"Chung","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2015.05.052_bib71","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1183\/09031936.00036707","article-title":"Increased activation of p38 MAPK in COPD","volume":"31","author":"Renda","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2015.05.052_bib72","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1183\/09031936.00071309","article-title":"Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma","volume":"35","author":"Bhavsar","year":"2010","journal-title":"Eur Respir J"},{"issue":"suppl\u00a01","key":"10.1016\/j.jaci.2015.05.052_bib73","doi-asserted-by":"crossref","first-page":"i77","DOI":"10.1136\/ard.2009.119479","article-title":"\u201cGo upstream, young man\u201d: lessons learned from the p38 saga","volume":"69","author":"Hammaker","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2015.05.052_bib74","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/0091270010397050","article-title":"An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease","volume":"52","author":"Lomas","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2015.05.052_bib75","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1136\/thoraxjnl-2012-202744","article-title":"Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial","volume":"68","author":"MacNee","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2015.05.052_bib76","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1164\/rccm.200408-1006OC","article-title":"Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice","volume":"171","author":"Duan","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib77","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1021\/jm200677b","article-title":"Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease","volume":"54","author":"Millan","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.jaci.2015.05.052_bib78","doi-asserted-by":"crossref","first-page":"L921","DOI":"10.1152\/ajplung.00250.2007","article-title":"TRX-ASK1-JNK signaling regulation of cell density-dependent cytotoxicity in cigarette smoke-exposed human bronchial epithelial cells","volume":"294","author":"Lee","year":"2008","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jaci.2015.05.052_bib79","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1164\/ajrccm.158.5.9706116","article-title":"Activation and localization of transcription factor, nuclear factor-kB, in asthma","volume":"158","author":"Hart","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib80","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/thorax.58.4.348","article-title":"Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations","volume":"58","author":"Caramori","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2015.05.052_bib81","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1124\/mol.105.019521","article-title":"IkappaB kinase-2-independent and -dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic","volume":"69","author":"Birrell","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jaci.2015.05.052_bib82","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrd1279","article-title":"The IKK NF-kappa B system: a treasure trove for drug development","volume":"3","author":"Karin","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2015.05.052_bib83","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.bbagrm.2010.05.004","article-title":"Inhibiting NF-kappaB activation by small molecules as a therapeutic strategy","volume":"1799","author":"Gupta","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jaci.2015.05.052_bib84","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.bbalip.2014.12.006","article-title":"PI3K signalling in inflammation","volume":"1851","author":"Hawkins","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jaci.2015.05.052_bib85","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1164\/rccm.200906-0937OC","article-title":"Targeting phosphoinositide-3-kinase-d with theophylline reverses corticosteroid insensitivity in COPD","volume":"182","author":"To","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib86","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2174\/156802609789044434","article-title":"Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) delta and gamma","volume":"9","author":"Ameriks","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.jaci.2015.05.052_bib87","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/B978-0-444-62652-3.00004-1","article-title":"Advances in the discovery of selective JAK inhibitors","volume":"52","author":"Menet","year":"2013","journal-title":"Prog Med Chem"},{"key":"10.1016\/j.jaci.2015.05.052_bib88","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejphar.2005.12.059","article-title":"Phosphodiesterase inhibitors in airways disease","volume":"533","author":"Chung","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jaci.2015.05.052_bib89","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1164\/rccm.201301-0021PP","article-title":"Phosphodiesterase-4 inhibitor therapy for lung diseases","volume":"188","author":"Beghe","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib90","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/thx.2006.075937","article-title":"Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD","volume":"62","author":"Grootendorst","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2015.05.052_bib91","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","article-title":"Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials","volume":"374","author":"Calverley","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2015.05.052_bib92","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(14)62410-7","article-title":"Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial","volume":"385","author":"Martinez","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2015.05.052_bib93","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1398-9995.2005.00931.x","article-title":"Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma","volume":"61","author":"Bousquet","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2015.05.052_bib94","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3797\/scipharm.1404-08","article-title":"Selective Phosphodiesterase 4B inhibitors: a review","volume":"82","author":"Azam","year":"2014","journal-title":"Sci Pharm"},{"key":"10.1016\/j.jaci.2015.05.052_bib95","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1476-5381.2009.00170.x","article-title":"Dual PDE3\/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease","volume":"157","author":"Banner","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaci.2015.05.052_bib96","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2213-2600(13)70187-5","article-title":"Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials","volume":"1","author":"Franciosi","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib97","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1378\/chest.121.6.1782","article-title":"Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin","volume":"121","author":"Kraft","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2015.05.052_bib98","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaci.2010.07.024","article-title":"A trial of clarithromycin for the treatment of suboptimally controlled asthma","volume":"126","author":"Sutherland","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.05.052_bib99","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1164\/rccm.200801-145OC","article-title":"Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations","volume":"178","author":"Seemungal","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib100","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib101","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(14)70019-0","article-title":"Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Uzun","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib102","doi-asserted-by":"crossref","first-page":"e0121257","DOI":"10.1371\/journal.pone.0121257","article-title":"Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis","volume":"10","author":"Ni","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2015.05.052_bib103","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1378\/chest.10-0196","article-title":"Chronic macrolide therapy in inflammatory airways diseases","volume":"138","author":"Friedlander","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2015.05.052_bib104","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharmthera.2014.03.003","article-title":"Azithromycin: mechanisms of action and their relevance for clinical applications","volume":"143","author":"Parnham","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jaci.2015.05.052_bib105","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/thoraxjnl-2014-206067","article-title":"Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma","volume":"70","author":"Essilfie","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2015.05.052_bib106","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/jpet.112.200733","article-title":"A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-kB inhibition","volume":"345","author":"Kobayashi","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaci.2015.05.052_bib107","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1183\/09031936.06.00001506","article-title":"Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages","volume":"28","author":"Hodge","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2015.05.052_bib108","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/bph.12187","article-title":"A novel macrolide\/fluoroketolide solithromycin (CEM-101) reverses corticosteroid insensitivity via PI3K pathway inhibition","volume":"169","author":"Kobayashi","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaci.2015.05.052_bib109","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1164\/rccm.200707-1134OC","article-title":"Clarithromycin targets neutrophilic airway inflammation in refractory asthma","volume":"177","author":"Simpson","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib110","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/thoraxjnl-2012-202698","article-title":"Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial","volume":"68","author":"Brusselle","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2015.05.052_bib111","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1164\/rccm.201402-0207OC","article-title":"Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy","volume":"189","author":"Han","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib112","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1016\/j.bmcl.2011.04.004","article-title":"Novel 12-membered non-antibiotic macrolides from erythromycin A; EM900 series as novel leads for anti-inflammatory and\/or immunomodulatory agents","volume":"21","author":"Sugawara","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jaci.2015.05.052_bib113","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/bph.12574","article-title":"Azithromycin analogue CSY0073 attenuates lung inflammation induced by LPS challenge","volume":"171","author":"Balloy","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaci.2015.05.052_bib114","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1128\/AAC.02316-12","article-title":"Solithromycin inhibition of protein synthesis and ribosome biogenesis in Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae","volume":"57","author":"Rodgers","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jaci.2015.05.052_bib115","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(09)60326-3","article-title":"Glucocorticoid resistance in inflammatory diseases","volume":"342","author":"Barnes","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2015.05.052_bib116","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jaci.2012.12.1564","article-title":"Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease","volume":"131","author":"Barnes","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.05.052_bib117","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1067\/mai.2002.122465","article-title":"p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma","volume":"109","author":"Irusen","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.05.052_bib118","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.jaci.2004.03.018","article-title":"Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients","volume":"113","author":"Matthews","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.05.052_bib119","doi-asserted-by":"crossref","first-page":"e41582","DOI":"10.1371\/journal.pone.0041582","article-title":"Restoration of corticosteroid sensitivity by p38 mitogen activated Protein kinase inhibition in peripheral blood mononuclear cells from severe asthma","volume":"7","author":"Mercado","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2015.05.052_bib120","first-page":"283","article-title":"Reversal of corticosteroid insensitivity by p38 MAPK inhibition in peripheral blood mononuclear cells from COPD","volume":"10","author":"Khorasani","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.jaci.2015.05.052_bib121","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1124\/mol.111.071993","article-title":"p38 MAP kinase-g Inhibition by long-acting b2 adrenergic agonists reversed steroid insensitivity in severe asthma","volume":"80","author":"Mercado","year":"2011","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jaci.2015.05.052_bib122","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1196\/annals.1321.007","article-title":"Modulation of glucocorticoid receptor function via phosphorylation","volume":"1024","author":"Ismaili","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaci.2015.05.052_bib123","doi-asserted-by":"crossref","first-page":"e27627","DOI":"10.1371\/journal.pone.0027627","article-title":"Defects of protein phosphatase 2A causes corticosteroid insensitivity in severe asthma","volume":"6","author":"Kobayashi","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2015.05.052_bib124","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.jaci.2013.05.028","article-title":"Rhinovirus infection causes steroid resistance in airway epithelium through nuclear factor kB and c-Jun N-terminal kinase activation","volume":"132","author":"Papi","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.05.052_bib125","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1365-2222.2009.03298.x","article-title":"Intrinsic asthma: not so different from allergic asthma but driven by superantigens?","volume":"39","author":"Barnes","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2015.05.052_bib126","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaci.2004.08.005","article-title":"Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase\/extracellular signal-regulated kinase (MEK-ERK) pathway","volume":"114","author":"Li","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.05.052_bib127","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1111\/j.1476-5381.2012.01923.x","article-title":"Corticosteroids and b2-agonists upregulate mitogen-activated protein kinase phosphatase 1: in\u00a0vitro mechanisms","volume":"166","author":"Manetsch","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaci.2015.05.052_bib128","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1084\/jem.20060336","article-title":"Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1","volume":"203","author":"Abraham","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib129","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1136\/thx.2007.090027","article-title":"Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared to non-severe asthma","volume":"63","author":"Bhavsar","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2015.05.052_bib130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2174\/187152807781696455","article-title":"Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases","volume":"6","author":"Hoi","year":"2007","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.jaci.2015.05.052_bib131","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/art.38689","article-title":"Macrophage migration inhibitory factor inhibits the antiinflammatory effects of glucocorticoids via glucocorticoid-induced leucine zipper","volume":"66","author":"Fan","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2015.05.052_bib132","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev.physiol.010908.163257","article-title":"Role of HDAC2 in the pathophysiology of COPD","volume":"71","author":"Barnes","year":"2009","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.jaci.2015.05.052_bib133","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1084\/jem.20050466","article-title":"Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kB suppression","volume":"203","author":"Ito","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib134","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1164\/rccm.200512-1930OC","article-title":"Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma","volume":"174","author":"Hew","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib135","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1164\/rccm.200305-659OC","article-title":"Histone acetylase and deacetylase activity in alveolar macrophages and blood monocytes in asthma","volume":"170","author":"Cosio","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib136","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1378\/chest.13-0835","article-title":"Passive smoking impairs histone deacetylase-2 in children with severe asthma","volume":"145","author":"Kobayashi","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2015.05.052_bib137","article-title":"Oxidative and nitrosative stress and histone deacetylase-2 activity in exacerbations of chronic obstructive pulmonary disease","author":"Footitt","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2015.05.052_bib138","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.1073\/pnas.132556899","article-title":"A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression","volume":"99","author":"Ito","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2015.05.052_bib139","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1084\/jem.20040416","article-title":"Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages","volume":"200","author":"Cosio","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib140","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1378\/chest.09-2363","article-title":"Treatment effects of low dose theophylline combined with an inhaled corticosteroid in COPD","volume":"137","author":"Ford","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2015.05.052_bib141","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1164\/rccm.200810-1570OC","article-title":"Inhibition of PI3Kd restores glucocorticoid function in smoking-induced airway inflammation in mice","volume":"179","author":"Marwick","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib142","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1183\/09031936.00158208","article-title":"Effect of theophylline plus beclometasone on lung function in smokers with asthma-a pilot study","volume":"33","author":"Spears","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2015.05.052_bib143","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1164\/ajrccm.151.6.7767539","article-title":"Immunomodulation by theophylline in asthma: demonstration by withdrawal of therapy","volume":"151","author":"Kidney","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib144","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1378\/chest.104.4.1101","article-title":"Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease","volume":"104","author":"Kirsten","year":"1993","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2015.05.052_bib145","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1124\/jpet.110.175950","article-title":"Nortriptyline reverses corticosteroid insensitivity by inhibition of PI3K-d","volume":"337","author":"Mercado","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaci.2015.05.052_bib146","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1164\/rccm.200803-380OC","article-title":"Decline in NRF2 regulated antioxidants in COPD lungs due to loss of its positive regulator DJ-1","volume":"178","author":"Malhotra","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib147","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.bbrc.2011.02.035","article-title":"Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress","volume":"406","author":"Mercado","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jaci.2015.05.052_bib148","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1172\/JCI45144","article-title":"Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients","volume":"121","author":"Malhotra","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2015.05.052_bib149","first-page":"2075","article-title":"Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties","volume":"8","author":"Wang","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jaci.2015.05.052_bib150","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib151","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1021\/jm5000529","article-title":"Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis","volume":"57","author":"Jiang","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.jaci.2015.05.052_bib152","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1165\/rcmb.2008-0012OC","article-title":"Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2","volume":"39","author":"Meja","year":"2008","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jaci.2015.05.052_bib153","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/bph.12187","article-title":"A novel macrolide\/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition","volume":"169","author":"Kobayashi","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaci.2015.05.052_bib154","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1124\/pr.111.004580","article-title":"Pharmacology and therapeutics of bronchodilators","volume":"64","author":"Cazzola","year":"2012","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jaci.2015.05.052_bib155","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1183\/09031936.00157711","article-title":"Does dynamic hyperinflation contribute to dyspnoea during exercise in patients with COPD?","volume":"40","author":"Guenette","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2015.05.052_bib156","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.tips.2011.04.003","article-title":"Novel bronchodilators for the treatment of chronic obstructive pulmonary disease","volume":"32","author":"Matera","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jaci.2015.05.052_bib157","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jaci.2011.04.039","article-title":"Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial","volume":"128","author":"Kerstjens","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.05.052_bib158","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1208606","article-title":"Tiotropium in asthma poorly controlled with standard combination therapy","volume":"367","author":"Kerstjens","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib159","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1152\/japplphysiol.00329.2007","article-title":"Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation","volume":"104","author":"Sorkness","year":"2008","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.jaci.2015.05.052_bib160","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJMoa1008770","article-title":"Tiotropium bromide step-up therapy for adults with uncontrolled asthma","volume":"363","author":"Peters","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib161","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S2213-2600(15)00031-4","article-title":"Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials","volume":"3","author":"Kerstjens","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib162","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.pupt.2009.06.002","article-title":"Alternative mechanisms for tiotropium","volume":"22","author":"Bateman","year":"2009","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaci.2015.05.052_bib163","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1183\/09031936.00136710","article-title":"Expression of muscarinic receptors by human macrophages","volume":"39","author":"Koarai","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2015.05.052_bib164","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/j.1365-2222.2010.03478.x","article-title":"Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma","volume":"40","author":"Ohta","year":"2010","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2015.05.052_bib165","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1183\/09031936.00146610","article-title":"Tiotropium inhibits pulmonary inflammation and remodelling in a guinea pig model of COPD","volume":"38","author":"Pera","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2015.05.052_bib166","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/thx.2010.139113","article-title":"QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease","volume":"65","author":"van Noord","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2015.05.052_bib167","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","article-title":"Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study","volume":"1","author":"Wedzicha","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib168","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1586\/17476348.2014.910457","article-title":"Recent advances in COPD disease management with fixed-dose long-acting combination therapies","volume":"8","author":"Bateman","year":"2014","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib169","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/bcp.12545","article-title":"New combination bronchodilators for COPD: current evidence and future perspectives","volume":"79","author":"Singh","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2015.05.052_bib170","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1586\/ers.11.26","article-title":"Triple inhalers for obstructive airways disease: will they be useful?","volume":"5","author":"Barnes","year":"2011","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib171","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1183\/09031936.00003814","article-title":"Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease","volume":"44","author":"Page","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2015.05.052_bib172","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1164\/rccm.200904-0492OC","article-title":"Efficacy and tolerability of budesonide\/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease","volume":"180","author":"Welte","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib173","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-146-8-200704170-00152","article-title":"Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial","volume":"146","author":"Aaron","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib174","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1164\/rccm.200903-0354OC","article-title":"Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial","volume":"181","author":"Castro","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.05.052_bib175","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1378\/chest.14-0536","article-title":"Bronchial thermoplasty: reappraising the evidence (or lack thereof)","volume":"146","author":"Iyer","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2015.05.052_bib176","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrd4025","article-title":"New anti-inflammatory treatments for chronic obstructive pulmonary disease","volume":"12","author":"Barnes","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2015.05.052_bib177","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaci.2011.11.006","article-title":"Severe asthma: advances in current management and future therapy","volume":"129","author":"Barnes","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.05.052_bib178","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jaci.2010.02.005","article-title":"Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: a prospective study using multiple samples","volume":"125","author":"Al-Samri","year":"2010","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674915009306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674915009306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:54:10Z","timestamp":1758790450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674915009306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":178,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0091674915009306"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2015.05.052","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic approaches to asthma\u2013chronic obstructive pulmonary disease overlap syndromes","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2015.05.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}